Hemostemix Inc. (HEM.V)
CAD 0.1
(26.67%)
CAD 0.1
(26.67%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -0.03 CAD | 59.49% |
| 2022 | -0.07 CAD | 32.0% |
| 2021 | -0.11 CAD | 54.17% |
| 2020 | -0.24 CAD | 25.0% |
| 2019 | -0.32 CAD | 21.95% |
| 2018 | -0.41 CAD | 26.79% |
| 2017 | -0.56 CAD | 50.0% |
| 2016 | -1.12 CAD | 0.88% |
| 2015 | -1.13 CAD | 18.71% |
| 2014 | -1.39 CAD | -178.0% |
| 2013 | -0.50 CAD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -0.01 CAD | -9.09% |
| 2024 Q1 | -0.01 CAD | 33.73% |
| 2023 Q1 | -0.02 CAD | 5.62% |
| 2023 Q4 | -0.01 CAD | -176.67% |
| 2023 Q3 | -0.00 CAD | 14.29% |
| 2023 FY | - CAD | 59.49% |
| 2023 Q2 | -0.00 CAD | 79.17% |
| 2022 Q1 | -0.03 CAD | 52.88% |
| 2022 FY | - CAD | 32.0% |
| 2022 Q2 | -0.02 CAD | 21.76% |
| 2022 Q3 | -0.01 CAD | 46.34% |
| 2022 Q4 | -0.02 CAD | -61.82% |
| 2021 Q2 | -0.02 CAD | -90.98% |
| 2021 Q4 | -0.06 CAD | -207.18% |
| 2021 Q1 | -0.01 CAD | 87.8% |
| 2021 Q3 | -0.02 CAD | 22.32% |
| 2021 FY | - CAD | 54.17% |
| 2020 FY | - CAD | 25.0% |
| 2020 Q4 | -0.10 CAD | -133.64% |
| 2020 Q3 | -0.04 CAD | 22.88% |
| 2020 Q2 | -0.06 CAD | -640.0% |
| 2020 Q1 | -0.01 CAD | 81.53% |
| 2019 FY | - CAD | 21.95% |
| 2019 Q3 | -0.09 CAD | -2.61% |
| 2019 Q2 | -0.09 CAD | 11.8% |
| 2019 Q4 | -0.04 CAD | 55.14% |
| 2019 Q1 | -0.10 CAD | 16.67% |
| 2018 FY | - CAD | 26.79% |
| 2018 Q4 | -0.12 CAD | -9.09% |
| 2018 Q2 | -0.11 CAD | -50.68% |
| 2018 Q1 | -0.07 CAD | -18.12% |
| 2018 Q3 | -0.11 CAD | 0.0% |
| 2017 Q2 | -0.14 CAD | 6.67% |
| 2017 Q4 | -0.06 CAD | 85.95% |
| 2017 Q3 | -0.44 CAD | -214.29% |
| 2017 FY | - CAD | 50.0% |
| 2017 Q1 | -0.15 CAD | 42.31% |
| 2016 FY | - CAD | 0.88% |
| 2016 Q2 | -0.18 CAD | 5.26% |
| 2016 Q3 | -0.47 CAD | -161.11% |
| 2016 Q4 | -0.26 CAD | 44.68% |
| 2016 Q1 | -0.19 CAD | 45.71% |
| 2015 Q1 | -0.25 CAD | 59.02% |
| 2015 FY | - CAD | 18.71% |
| 2015 Q4 | -0.35 CAD | -25.0% |
| 2015 Q3 | -0.28 CAD | -3.7% |
| 2015 Q2 | -0.27 CAD | -8.0% |
| 2014 FY | - CAD | -178.0% |
| 2014 Q1 | -0.17 CAD | 41.38% |
| 2014 Q3 | -0.29 CAD | -2064.18% |
| 2014 Q2 | -0.01 CAD | 92.12% |
| 2014 Q4 | -0.61 CAD | -110.34% |
| 2013 Q3 | -0.30 CAD | -3900.0% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q1 | -1.38 CAD | 0.0% |
| 2013 Q4 | -0.29 CAD | 3.33% |
| 2013 Q2 | -0.01 CAD | 99.46% |
| 2012 Q3 | - CAD | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Arch Biopartners Inc. | -0.05 CAD | 43.152% |
| Covalon Technologies Ltd. | -0.18 CAD | 83.167% |
| Universal Ibogaine Inc. | -0.06 CAD | 46.372% |
| Kane Biotech Inc. | -0.04 CAD | 15.599% |
| MedMira Inc. | -0.00 CAD | -697.368% |
| Marvel Biosciences Corp. | -0.06 CAD | 47.578% |
| NervGen Pharma Corp. | -0.38 CAD | 92.026% |
| XORTX Therapeutics Inc. | -1.44 CAD | 97.896% |